BHV-1300
Asset
Bispecific extracellular pan-IgG degrader targeting IgG to asialoglycoprotein receptors
- Stage
- Phase 3
- Modality
- Protein or enzyme
- Target
- Inflammation
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Graves' disease
Phase 3, prnewswire.com, 8 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners2
- Evidence for its targets2
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.